Variability in the Population Pharmacokinetics of Pyrazinamide in South African Tuberculosis Patients

Overview

Journal Eur J Clin Pharmacol

Specialty Pharmacology

Date 2006 May 11

PMID 16685561

Citations 47

Authors

Justin J Wilkins

Grant Langdon

Helen McIlleron

Goonaseelan Colin Pillai

Peter J Smith

Ulrika S H Simonsson

Affiliations

Soon will be listed here.

Abstract

Objective: This study was designed to characterize the population pharmacokinetics of pyrazinamide in South African pulmonary tuberculosis patients, with special reference to interindividual and interoccasional variability (IIV and IOV, respectively).

Methods: Concentration-time measurements obtained from 227 patients receiving oral doses of pyrazinamide were pooled to create a dataset containing 3,092 data points spanning multiple dosing occasions. The software program NONMEM was used to analyze the data.

Results: A one-compartment model with first-order absorption, including a zero-order component describing release from formulation, and first-order elimination best described the data. The absorption rate constant was estimated to be bimodally distributed between two distinct subgroups, fast and slow, in approximately even proportion. Absorption rate was threefold greater in fast absorbers (3.56 h(-1)) in comparison to slow absorbers (1.25 h(-1)). Typical values of oral clearance and apparent volume of distribution were estimated as 3.42 L h(-1) and 29.2 l, respectively. IOV was supported in oral clearance (0.0238, variance) and absorption rate (0.623, variance). The duration of zero-order absorption was estimated as 0.290 h, and was quite variable between patients (0.957, variance).

Conclusion: The absorption of pyrazinamide in the studied population was highly variable and two separate subpopulations were identified. IOV accounted for a proportion of the variability in clearance and the absorption rate constant.

Citing Articles

Timing of recurrence after treatment of pulmonary TB.

Mithunage C, Denning D IJTLD Open. 2024; 1(10):456-465.

PMID: 39398436 PMC: 11467853. DOI: 10.5588/ijtldopen.24.0222.

Pyrazinamide Safety, Efficacy, and Dosing for Treating Drug-Susceptible Pulmonary Tuberculosis: A Phase 3, Randomized Controlled Clinical Trial.

Xu A, Velasquez G, Zhang N, Chang V, Phillips P, Nahid P Am J Respir Crit Care Med. 2024; 210(11):1358-1369.

PMID: 39012226 PMC: 11622436. DOI: 10.1164/rccm.202401-0165OC.

Risk adjustment model for tuberculosis compared to non-tuberculosis mycobacterium or latent tuberculosis infection: Center for Personalized Precision Medicine of Tuberculosis (cPMTb) cohort database.

Seo W, Koo H, Kang J, Kang J, Park S, Kang H BMC Pulm Med. 2023; 23(1):471.

PMID: 38001469 PMC: 10675857. DOI: 10.1186/s12890-023-02646-7.

Development of a population pharmacokinetic model of pyrazinamide to guide personalized therapy: impacts of geriatric and diabetes mellitus on clearance.

Kim R, Jayanti R, Lee H, Kim H, Kang J, Park I Front Pharmacol. 2023; 14:1116226.

PMID: 37305528 PMC: 10250603. DOI: 10.3389/fphar.2023.1116226.

Pharmacokinetics of antitubercular drugs in patients hospitalized with HIV-associated tuberculosis: a population modeling analysis.

Abdelgawad N, Chirehwa M, Schutz C, Barr D, Ward A, Janssen S Wellcome Open Res. 2024; 7:72.

PMID: 37008250 PMC: 10050909. DOI: 10.12688/wellcomeopenres.17660.3.

References

Mandema J, Verotta D, Sheiner L . Building population pharmacokinetic--pharmacodynamic models. I. Models for covariate effects. J Pharmacokinet Biopharm. 1992; 20(5):511-28. DOI: 10.1007/BF01061469. View

Shishoo C, Shah S, Rathod I, Savale S, Vora M . Impaired bioavailability of rifampicin in presence of isoniazid from fixed dose combination (FDC) formulation. Int J Pharm. 2001; 228(1-2):53-67. DOI: 10.1016/s0378-5173(01)00831-6. View

Zhu M, Starke J, Burman W, Steiner P, Stambaugh J, Ashkin D . Population pharmacokinetic modeling of pyrazinamide in children and adults with tuberculosis. Pharmacotherapy. 2002; 22(6):686-95. DOI: 10.1592/phco.22.9.686.34067. View

McDermott W, TOMPSETT R . Activation of pyrazinamide and nicotinamide in acidic environments in vitro. Am Rev Tuberc. 1954; 70(4):748-54. DOI: 10.1164/art.1954.70.4.748. View

Heifets L . Pyrazinamide sterilizing activity in vitro against semidormant Mycobacterium tuberculosis bacterial populations. Am Rev Respir Dis. 1992; 145(5):1223-5. DOI: 10.1164/ajrccm/145.5.1223. View

Yeager R, MUNROE W, Dessau F . Pyrazinamide (aldinamide) in the treatment of pulmonary tuberculosis. Am Rev Tuberc. 1952; 65(5):523-46. View

Jonsson E, Karlsson M . Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed. 1999; 58(1):51-64. DOI: 10.1016/s0169-2607(98)00067-4. View

Salfinger M, Heifets L . Determination of pyrazinamide MICs for Mycobacterium tuberculosis at different pHs by the radiometric method. Antimicrob Agents Chemother. 1988; 32(7):1002-4. PMC: 172333. DOI: 10.1128/AAC.32.7.1002. View

Konno K, FELDMANN F, McDermott W . Pyrazinamide susceptibility and amidase activity of tubercle bacilli. Am Rev Respir Dis. 1967; 95(3):461-9. DOI: 10.1164/arrd.1967.95.3.461. View

10.

Mitchison D . Role of individual drugs in the chemotherapy of tuberculosis. Int J Tuberc Lung Dis. 2000; 4(9):796-806. View

11.

TARSHIS M, WEED Jr W . Lack of significant in vitro sensitivity of Mycobacterium tuberculosis to pyrazinamide on three different solid media. Am Rev Tuberc. 1953; 67(3):391-5. DOI: 10.1164/art.1953.67.3.391. View

12.

Peloquin C, Jaresko G, Yong C, Keung A, Bulpitt A, Jelliffe R . Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide. Antimicrob Agents Chemother. 1998; 41(12):2670-9. PMC: 164187. DOI: 10.1128/AAC.41.12.2670. View

13.

Ellard G . Absorption, metabolism and excretion of pyrazinamide in man. Tubercle. 1969; 50(2):144-58. DOI: 10.1016/0041-3879(69)90020-8. View

14.

Smith P, Van Dyk J, Fredericks A . Determination of rifampicin, isoniazid and pyrazinamide by high performance liquid chromatography after their simultaneous extraction from plasma. Int J Tuberc Lung Dis. 1999; 3(11 Suppl 3):S325-8; discussion S351-2. View

15.

Agrawal S, Panchagnula R . Implication of biopharmaceutics and pharmacokinetics of rifampicin in variable bioavailability from solid oral dosage forms. Biopharm Drug Dispos. 2005; 26(8):321-34. DOI: 10.1002/bdd.464. View

16.

Singh S, Mariappan T, Shankar R, Sarda N, Singh B . A critical review of the probable reasons for the poor variable bioavailability of rifampicin from anti-tubercular fixed-dose combination (FDC) products, and the likely solutions to the problem. Int J Pharm. 2001; 228(1-2):5-17. DOI: 10.1016/s0378-5173(01)00754-2. View

17.

Zhang Y, Scorpio A, Nikaido H, Sun Z . Role of acid pH and deficient efflux of pyrazinoic acid in unique susceptibility of Mycobacterium tuberculosis to pyrazinamide. J Bacteriol. 1999; 181(7):2044-9. PMC: 93615. DOI: 10.1128/JB.181.7.2044-2049.1999. View

18.

Wilkins J . NONMEMory: a run management tool for NONMEM. Comput Methods Programs Biomed. 2005; 78(3):259-67. DOI: 10.1016/j.cmpb.2005.02.003. View

19.

Wahlby U, Jonsson E, Karlsson M . Assessment of actual significance levels for covariate effects in NONMEM. J Pharmacokinet Pharmacodyn. 2001; 28(3):231-52. DOI: 10.1023/a:1011527125570. View